About ACST

Founded: 2002
Employees: n/a
CEO: Prashant Kohli
WebsiteView website: www.acastipharma.com

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Recent ACST News & Updates

Announcement • Jan 26

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

Acasti Pharma Inc. announced that it has received notification from the NASDAQ Listing Qualifications Department ("NASDAQ") that it is eligible for an additional 180 calendar days, or until July 24, 2023, to regain compliance with the minimum $1.00 per share requirement for continued listing. On July 27, 2022, Acasti received notification from NASDAQ for not maintaining a minimum bid price of $1.00 per share for 30 consecutive business days (the “Minimum Bid Price Rule”). The Company was given 180 calendar days, or until January 23, 2023, to regain compliance. On January 24, 2023, Acasti received notification from NASDAQ that it is eligible for an additional 180 calendar days, or until July 24, 2023, to regain compliance with the Minimum Bid Price Rule. Acasti was granted the second extension because it meets the continued listing requirements for the market value of publicly held shares and all other initial listing standards for NASDAQ Capital Market, except for the bid price requirement. To regain compliance, Acasti's shares must close at $1.00 per share or more for a minimum of 10 consecutive business days prior to July 24, 2023. Acasti will continue to monitor the bid price for its common shares and consider various available options if Acasti’s common shares do not trade at a level that is likely to regain compliance with the Minimum Bid Price Rule.

Recent updates

No updates

Acasti Pharma Inc. Stock Price

ACST Share Price Performance

ACST Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

Acasti Pharma Inc. Key Details

About ACST

Recent ACST News & Updates

Acasti Pharma (CVE:ACST) Is In A Good Position To Deliver On Growth Plans

Acasti Pharma Inc. to Report Q3, 2023 Results on Feb 14, 2023

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

Recent updates

Acasti Pharma Inc. Competitors

Optimi Health

C21 Investments

ZYUS Life Sciences

Medicenna Therapeutics